🇺🇸 FDA
Pipeline program

GEMCITABINE ARROW 40 mg/ml, solution à diluer pour perfusion, Berzosertib (M6620)

IB 2018-04

Phase 2 small_molecule active

Quick answer

GEMCITABINE ARROW 40 mg/ml, solution à diluer pour perfusion, Berzosertib (M6620) for Adult patients with locally advanced/unresectable and/or metastatic soft-tissue leiomyosarcomas. is a Phase 2 program (small_molecule) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Institut für biomedizinische Analytik NMR-Imaging GmbH
Indication
Adult patients with locally advanced/unresectable and/or metastatic soft-tissue leiomyosarcomas.
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials